Cargando…

Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?

Detalles Bibliográficos
Autores principales:	Ozgur Yurttas, Nurgul, Eskazan, Ahmet Emre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829637/ https://www.ncbi.nlm.nih.gov/pubmed/31373213 http://dx.doi.org/10.1177/1076029619866925

Ejemplares similares

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
por: Tiribelli, Mario, et al.
Publicado: (2019)

Candida esophagitis incidentally detected by 18F‐FDG PET/CT in a patient with CNS lymphoma
por: Bayar, Melikşah, et al.
Publicado: (2021)

The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia
por: Saydam, Guray, et al.
Publicado: (2022)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
por: Wada, Yoshihiro, et al.
Publicado: (2012)

Does BRAF Mutation and Extracellular Signal Regulated Kinase Expression in Patients With Colorectal Cancer Have Any Prognostic Significance?
por: Baek, Moo Jun
Publicado: (2015)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

To Have and Have Not: Intrinsic Platelet Hyperreactivity?
por: Laine, Marc, et al.
Publicado: (2018)

Tyrosine kinase inhibitors induced thyroid dysfunction: myth or reality?
por: Malhotra, Anjli, et al.
Publicado: (2023)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges
por: Oduah, Eziafa I., et al.
Publicado: (2022)

Pneumoperitoneum After Percutaneous Endoscopic Gastrostomy: Does It Have Clinical Significance?
por: Lee, Ju Yup, et al.
Publicado: (2015)

Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
por: Park, Tae Ju, et al.
Publicado: (2016)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

Chronic Myeloid Leukemia in Children and Adolescents: The Achilles Heel of Oncogenesis and Tyrosine Kinase Inhibitors
por: Moschovi, Maria, et al.
Publicado: (2021)

Asciminib in chronic myeloid leukemia: many questions still remain to be answered
por: Eşkazan, Ahmet Emre
Publicado: (2021)

Varying effects of tyrosine kinase inhibitors on platelet function—A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
por: Deb, Suryyani, et al.
Publicado: (2019)

Receptor Tyrosine Kinases — Expanding Horizons
por: Hafizi, Sassan
Publicado: (2014)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Tyrosine kinase – Role and significance in Cancer
por: Paul, Manash K., et al.
Publicado: (2004)

Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment
por: Tullemans, Bibian M. E., et al.
Publicado: (2021)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
por: Zhang, Shannon S., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity
por: Zheng, Tony J., et al.
Publicado: (2022)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2022)

MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
por: Gramantieri, Laura, et al.
Publicado: (2022)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease
por: Kanaan, Rana, et al.
Publicado: (2017)

Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide
por: Lim, I. Vern, et al.
Publicado: (2023)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_is6nt656a43lhpth9dih70qbut